The results in animal and cell studies in relation to the MetS have shown that GLSs derivatives (ITCs and indoles) treatment reduces fat deposition in WAT and liver, decreases proliferation and differentiation of adipocytes, promotes WAT browning with an increase of energy expenditure, improves insulin sensitivity, reduces inflammation and decreases food intake. This evidence concerns the gene INS and metabolic syndrome.